SMARCB1 Pre-design Chimera RNAi
- Known as:
- SMARCB1 Pre-design Chimera RNAi
- Catalog number:
- H00006598-R01
- Product Quantity:
- 10 nmol
- Category:
- -
- Supplier:
- Abno
- Gene target:
- SMARCB1 Pre-design Chimera RNAi
Related genes to: SMARCB1 Pre-design Chimera RNAi
- Gene:
- SMARCB1 NIH gene
- Name:
- SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily b, member 1
- Previous symbol:
- SNF5L1
- Synonyms:
- BAF47, Ini1, Snr1, hSNFS, Sfh1p, RDT, PPP1R144, SNF5
- Chromosome:
- 22q11.23
- Locus Type:
- gene with protein product
- Date approved:
- 1995-08-21
- Date modifiied:
- 2019-04-23
Related products to: SMARCB1 Pre-design Chimera RNAi
Related articles to: SMARCB1 Pre-design Chimera RNAi
- Epithelioid sarcoma (ES) accounts for < 1% of all sarcomas and is characterized by predominantly epithelioid cytologic features together with epithelial immunophenotypic properties. Intraoral involvement is apparently rare with only 17 previously reported examples. Herein, the clinicopathologic and immunohistochemical features of 5 additional oral ES cases are presented with review of the literature. - Source: PubMed
Publication date: 2026/05/29
Argyris Prokopios PRubrecht Ashlie EBilodeau Elizabeth AFoss Robert DKoutlas Ioannis G - SMARCB1-deficient carcinomas exhibit a broad anatomical distribution. Herein, we characterize primary SMARCB1-deficient intestinal carcinoma (SdIC), encompassing both colorectal and small bowel origins. As an exceptionally rare and aggressive entity, SdIC presents significant diagnostic challenges due to its propensity to mimic other malignancies and the paucity of comprehensive clinical data, thereby hindering early recognition and effective management. - Source: PubMed
Publication date: 2026/05/26
Shi ChenxiLi San-EnJiang NanYan MengJiang Lili - Variants in SMARCB1, encoding a core subunit of the BAF chromatin remodeling complex, are associated with intellectual developmental disorders, particularly Coffin-Siris Syndrome (CSS), though the genotype-phenotype spectrum remains incompletely defined. This study aims to assess correlations between SMARCB1 variant location and phenotypic manifestations. - Source: PubMed
Publication date: 2026/05/27
Saad RamyGigli Clementina Cobollivan der Sluijs Pleuntje JWilson Jon RHsieh Tzung-ChienMcConnell Vivienne P MBacino CarlosBird Lynne MAdam ShelinClarke LorneCobben Jan MTravessa AndréFaivre LaurenceFarholt StenseGregersen Pernillevan Hasselt JosLahiri NayanaPalmer Elizabeth ESheffer RuthClayton-Smith JillWilnai YaelDeshpande CharuMorton Jenny E VClement EmmaSanten Gijs W EDias Cristina - Atypical teratoid/rhabdoid tumor (AT/RT) is a rare and aggressive pediatric embryonal tumor of the central nervous system with marked histological and immunophenotypic heterogeneity, which can make diagnosis difficult in some cases. This study aimed to summarize the clinicopathological and molecular features of pediatric AT/RT and to evaluate an HE-IHC dual-path deep learning model as an auxiliary diagnostic approach. Clinical, histopathological, immunophenotypic, ultrastructural, and fluorescence in situ hybridization (FISH) data were retrospectively collected from 18 children with AT/RT treated at Beijing Children's Hospital between February 2010 and April 2021. A total of 361 pathological images were used to train and test a ResNet50-based dual-path classification model with transfer learning and feature fusion. An additional independent test set of 175 histological and immunohistochemical images from six newly collected patients was used for supplementary validation. The mean age at diagnosis was 2 years and 3 months. All cases showed loss of INI1 expression, positivity for CK and EMA, and a high Ki-67 index. FISH analysis identified SMARCB1 deletion in 7 of 15 tested cases. In the original image-based test set, the dual-path model achieved an accuracy of 90.91%, compared with 81.82% for the model without transfer learning, 86.36% for the single-path immunohistochemistry model, and 50.00% for the single-path histological model. In the additional independent test set, the trained model correctly classified all 175 images. Pediatric AT/RT shows diverse clinicopathological features and complex SMARCB1 alteration patterns. The HE-IHC dual-path model showed encouraging preliminary performance for auxiliary pathological assessment; however, larger multicenter cohorts with molecular subgroup annotation are needed for further validation before routine clinical application. - Source: PubMed
Publication date: 2026/05/16
Tian JianZhang NanDeng ZhijuanWang JianwenZheng Wentao - Oesophageal adenocarcinoma (OAC) incidence continues to rise in developed countries. Despite advances in deciphering cancer genomes and oncogenic pathways, precision therapies for OAC remain limited. An expansion of precision therapy repertoire in OAC is urgently required. - Source: PubMed
Publication date: 2026/05/25
Sharma SowmyaWong Ho YiJohnston Rebecca LKoufariotis Lambros TWood ScottHollway GeorginaAoude Lauren GDavidson Aimee LPearson John VLin Frank PBarbour Andrew PWaddell Nicola